Compare Phillips 66 (PSX) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Summit Therapeutics Inc — how do they compare? Phillips 66 trades at $262.98 (market cap $104.06B), while Summit Therapeutics Inc trades at $17.58 (market cap $13.98B). The key difference: Phillips 66 is far larger — about 7.4× Summit Therapeutics Inc's market cap, and Phillips 66 pays a 1.95% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PSX | SMMT | |
|---|---|---|
Market Cap | $104.06B | $13.98B |
Sector | Energy | Health |
52-Week High | $260.78 | $26.38 |
52-Week Low | $126.76 | $12.43 |
Enterprise Value | $120.52B | $13.31B |
Dividend Yield | 1.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $259.14, up 1.59% over 24 hours and near its 52-week high, with bullish technical indicators and strong support at $258. The stock shows robust fundamentals, including a P/E of 14.79 and ROE of 24.02%, while recent quarterly earnings consistently beat expectations. Positive news highlights refining strength amid elevated energy prices, with institutional buying supporting momentum.
Outlook remains favorable due to earnings growth and cost initiatives, but risks include volatile refining margins and debt levels. Analysts are bullish with a $242.45 consensus target, though current price exceeds it, suggesting cautious optimism for further upside if operational targets are met.
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
